Advertisement

Topics

Companies Related to "Liver Cancer Pipeline Review 2015" [Most Relevant Company Matches] - Page: 5 RSS

21:52 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Liver Cancer Pipeline Review 2015" found in our extensive corporate database of over 50,000 company records.

Showing "Liver Cancer Pipeline Review 2015" Companies 101–125 of 3,500+

Relevant

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.


BIND Therapeutics, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an...

Probably Relevant

Becker Professional Education

Becker Professional Education, a part of DeVry Education Group (NYSE: DV), is a global leader in professional education serving the accounting, project management and healthcare professions. Nearly half a million professionals have prepared to advance their careers through its CPA Exam Review, ACCA® Courses, PMP® Exam Review, USMLE® Review and Con...


Morphotek Inc.

Morphotek is a biopharmaceutical company developing therapeutic monoclonal antibodies through the use of a proprietary human antibody technology. The company employs its technology to discover and develop optimized antibodies for the treatment of cancer, inflammatory, and infectious diseases. Morphotek currently has two products in clinical development and is positioned to file INDs for additional...

Cohen Children’s Medical Center

Opened in 1983, the Steven and Alexandra Cohen Children’s Medical Center of New York is home to about 675 pediatricians, including 200 full-time physicians, and a total workforce of more than 1,200, including more than 500 nurses. For the ninth consecutive year in 2015, Cohen’s was ranked among the best children’s hospitals in the nation in U.S. Ne...

AIMM Therapeutics B.V.

AIMM Therapeutics (AIMM) is a leading antibody company that based on its synergistic, state-of-the-art antibody technology platform develops high affinity human monoclonal antibodies from immortalized and selected B cells of individuals who produce antibodies with high therapeutic value. AIMM antibodies can be further affinity matured in a proprietary process ...

Nativis Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or...

Endocare, Inc.

Endocare, Inc.--www.endocare.com-- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors...

Celator Pharmaceuticals

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a na...

Millennium Pharmaceuticals, Inc.

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the h...

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...

Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic ...

Indevus Pharmaceuticals

We acquire, develop and commercialize products for multiple therapeutic areas, with a primary commitment to urology, gynecology and men's health. Our robust clinical-stage pipeline has the potential to improve the quality of life for millions of patients. We are focused on individual compounds, rather than on earlier stage, relatively unproven drug discovery technologies. We continually seek produ...

Canadian Liver Foundation

The Canadian Liver Foundation

ProNAi Therapeutics, Inc.

ProNAi Therapeutics, founded in 2004, has a proprietary and differentiated DNA interference (DNAi®) technology. DNAi utilizes single-stranded, unmodified, phosphodiester DNA sequences designed against genomic DNA to modulate gene transcription. In addition to PNT2258, the company has an expanding pipeline of DNAi leads for over 30 cancer and non-cancer ...

Teva Pharmaceutical Industries Ltd. & OncoGenex Pharmaceuticals, Inc.

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the le...

ProlX Pharmaceuticals, Corp.

ProlX Pharmaceuticals (ProlX) is a biopharmaceutical company dedicated to the discovery of novel therapeutics for the treatment of cancer. The Company is building a diversified pipeline utilizing a target-directed combinatorial chemistry approach to accelerate the design and development of small molecule drug leads. ProlX’s drug discovery program is focused on targeting redox regulation and sur...

PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is Spain's first anti-cancer drug. It is currently approved for soft tissue sarcoma (STS) in 25 countries outside the EEA, and in 5 of those countries for platinum-sensitive recurrent ovarian cancer (ROC) as well. Yondelis(R) is approved ...

Lung Therapeutics, Inc.

Lung Therapeutics, Inc. is a pharmaceutical company formed to leverage 25 years of leading research in lung injury and disease by pursuing niche, orphan drug indications for which there is no current effective therapeutic option. Current pipeline programs include LTI-01 Pleural Effusion (PE) with Loculation, LTI-02 Acute Lung Injury (ALI) and LTI-03 Idiopa...

Progenity Inc.

Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive ...

NewLink Genetics

NewLink Genetics is a private biopharmaceutical company with innovative technologies that are powering a late stage pipeline targeted at tough to treat cancers and infectious disease. NewLink's two complementary technology platforms target separate mechanisms that are commonly utilized by different cancer types to avoid immune system detection and destruction. The company's HyperAcute® cancer imm...

Atlanta Gastroenterology Associates

Founded in 1976, Atlanta Gastroenterology Associates (AGA) is one of the largest gastroenterology practices in the country dedicated to the detection and treatment of digestive and liver diseases, as well as colon cancer. With offices located throughout Metro Atlanta and North Georgia – including seven pediatric offices – its board-certified phys...

AIMM Therapeutics

AIMM Therapeutics (AIMM) is a leading antibody company that based on its synergistic, state-of-the-art antibody technology platform develops high affinity human monoclonal antibodies from immortalized and selected B cells of individuals who produce antibodies with high therapeutic value. AIMM antibodies can be further affinity matured in a proprietary process ...

CMO Consulting, Inc.

CMO Consulting is led by Edward Garmey, M.D. a former academic hematologist-oncologist at Memorial Sloan-Kettering Cancer Center with a successful industry track-record comprising over a decade of senior leadership experience including seven prior CMO roles. CMO Consulting provides its clients, ranging from blue-chip venture capital firms to start-ups and ...


More From BioPortfolio on "Liver Cancer Pipeline Review 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks